Ovid TherapeuticsOVID -1.28%48 Return-on-Tangible-Equity is -41.32% as of Mar. 2026. GuruFocus rates OVID with a GF Score™ of 48/100 and a GF Value™ of $8.46 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 1,200 Biotechnology companies, Ovid Therapeutics ranks better than 61.17% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Ovid Therapeutics's annualized net income for the quarter that ended in Mar. 2026 was $-67.95 Mil. Ovid Therapeutics's average shareholder tangible equity for the quarter that ended in Mar. 2026 was $164.46 Mil. Therefore, Ovid Therapeutics's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was -41.32%.
The historical rank and industry rank for Ovid Therapeutics's Return-on-Tangible-Equity or its related term are showing as below:
OVID'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -143.59 Med: -42.91 Max: 110.22
Current: -24.73
During the past 11 years, Ovid Therapeutics's highest Return-on-Tangible-Equity was 110.22%. The lowest was -143.59%. And the median was -42.91%.
OVID's Return-on-Tangible-Equity is ranked better than 61.17% of 1200
companies
in the Biotechnology industry
Industry Median: -42.435
vs OVID: -24.73
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Ovid Therapeutics Return-on-Tangible-Equity Related Terms
Ovid Therapeutics Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Ovid Therapeutics's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OVID vs ARTV, CCCC, RZLT: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Ovid Therapeutics's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ovid Therapeutics Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ovid Therapeutics's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Ovid Therapeutics's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -41.32% mean?
Ovid Therapeutics (OVID) has a Return-on-Tangible-Equity of -41.32% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Ovid Therapeutics and its competitors. According to the industry distribution chart, Ovid Therapeutics ranks #466 out of 1200 companies in the Biotechnology industry, placing it in the top 38.8%.
Is Ovid Therapeutics' Return-on-Tangible-Equity too high?
Ovid Therapeutics' current Return-on-Tangible-Equity is -41.32%. Based on the distribution chart, Ovid Therapeutics ranks #466 out of 1200 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Ovid Therapeutics has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ovid Therapeutics' Return-on-Tangible-Equity compare to ARTV and CCCC?
According to the Biotechnology industry distribution chart, Ovid Therapeutics ranks #466 out of 1200 companies for Return-on-Tangible-Equity. This puts Ovid Therapeutics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Ovid Therapeutics and its competitors. Ovid Therapeutics's current Return-on-Tangible-Equity is -41.32%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ovid Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Ovid Therapeutics (OVID) is currently considered Possible Value Trap. The stock's GF Value™ is $8.46, compared to a current price of $2.69 — trading 68.2% below its estimated fair value. The current Return-on-Tangible-Equity is -41.32%. Ovid Therapeutics' overall GF Score™ is 48/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Ovid Therapeutics (OVID), the current Return-on-Tangible-Equity is -41.32% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ovid Therapeutics (OVID) Overvalued in 2026?
Based on GuruFocus' analysis, Ovid Therapeutics stock appears to be undervalued.
The current stock price of $2.69 is trading 68.2% below its estimated GF Value™ of $8.46.
GuruFocus considers Ovid Therapeutics to be Possible Value Trap.
Key valuation signals for OVID:
Return-on-Tangible-Equity: -41.32%
GF Value™: $8.46 vs. price of $2.69 (68.2% below fair value)
No single metric tells the full story. See the OVID stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
48GF Score
Get the complete analysis for OVID
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OVID has been successfully added to your 
